R01 CA65537-16/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.

Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, Loggers ET, Rodler E, Eary JF, Conrad EU 3rd, Jones RL, Yee C. Pollack SM, et al. Cancer. 2012 Sep 15;118(18):4564-70. doi: 10.1002/cncr.27446. Epub 2012 Feb 22. Cancer. 2012. PMID: 22359263 Free PMC article.

NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.

Pollack SM, Li Y, Blaisdell MJ, Farrar EA, Chou J, Hoch BL, Loggers ET, Rodler E, Eary JF, Conrad EU 3rd, Jones RL, Yee C. Pollack SM, et al. PLoS One. 2012;7(2):e32165. doi: 10.1371/journal.pone.0032165. Epub 2012 Feb 27. PLoS One. 2012. PMID: 22384167 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2 results

Search Page

Filters